Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide

Carcinogenesis

Volumn 20, Issue 2, 1999, Pages 229-236

  Jinno, Hiromitsu ^a,b   Steiner, Melissa G ^b   Mehta, Rajendra G ^c   Osborne, Michael P ^a,b   Telang, Nitin T ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DRUG METABOLITE; FENRETINIDE; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER INHIBITION; CELL PROLIFERATION; CELL TRANSFORMATION; COLONY FORMATION; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0032908267     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.2.229     Document Type: Article

References (64)

1. Landis, S.H., Murray, T., Bolden, S. and Wingo, P.A. (1998) Cancer statistics, 1998. CA Cancer J. Clin., 48, 6-29.
2. Torrisi, R., Pensa, F., Orengo, M.A., Catsafados, E., Pouzani, P., Boccardo, E., Costa, A. and Decensi, A. (1993) The synthetic retinoid fenretinide lowers plasma IGF-I levels in breast cancer patients. Cancer Res., 53, 4769-4771.
3. Decensi, A., Formelli, F., Torrisi, R. and Costa, A. (1993) Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate end points. J. Cell. Biochem., 17G, 226-233.
4. Smith, M.A., Parkinson, D.R., Cheson, B.D. and Friedman, M.A. (1992) Retinoids in cancer therapy. J. Clin. Oncol., 10, 839-864.
5. Costa, A., Formelli, F., Chiesa, F., Decensi, A., Depalo, G. and Veronesi, U. (1994) Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res., 54 (suppl.), 2032-2037.
6. Cobleigh, M.A., Dowlatshahi, K., Deutsch, T.A. et al. (1993) Phase I/II trial of tamoxifen with or without fenretinide, an analogue of vitamin A, in women with metastatic hreast cancer. J. Clin. Oncol., 11, 474-477.
7. Costa, A., DePalo, G., Decensi, A., Formelli, F., Chiesa, F., Nava, M., Camerini, T., Marubini, E. and Veronesi, U. (1995) Retinoids in cancer prevention clinical trials with the synthetic analogue fenretinide. Ann. NY Acad. Sci., 768, 148-162.
8. Telang, N.T., Bradlow, H.L. and Osborne, M.P. (1992) Molecular and endocrine hiomarkers in noninvolved breast: relevance to cancer chemoprevention. J. Cell. Biochem., 16G, 161-169.
9. Telang, N.T., Narayanan, R., Bradlow, H.L. and Osborne, M.P. (1991) Coordinated expression of intermediate biomarkers for tumorigenic transformation in Ras transfected mouse mammary epithelial cells. Breast Cancer Res. Treat., 18, 155-163.
10. Telang, N.T., Osborne, M.P., Sweterlitsch, L. and Narayanan, R. (1990) Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression. Cell Regul., 1, 863-872.
11. Telang, N.T., Katdare, M., Bradlow, H.L. and Oshorne, M.P. (1997) Estradiol metabolism: an endocrine biomarker for modulation of human mammary carcinogenesis. Environ. Health Perspect., 105, 559-564.
12. Telang, N.T., Katdare, M., Bradlow, H.L., Osborne, M.P. and Fishman, J. (1997) Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for hreast cancer prevention by the phytochemical indole-3-carbinol. Proc. Soc. Exp. Biol. Med., 216, 246-252.
13. Katdare, M., Osborne, M.P. and Telang, N.T. (1998) Inhibition of aberrant proliferation and induction of apoptosis in preneoplastic human mammary epithelial cells by natural phytochemicals. Oncol. Rep., 5, 311-315.
14. Sporn, M.B. and Roberts, A.B. (1983) Role of retinoids in differentiation and carcinogenesis. Cancer Res., 43, 3034-3040.
15. Moon, R.C., McCormick, D.L. and Mehta, R.G. (1983) Inhibition of carcinogenesis by retinoids. Cancer Res., 43, 2469S-2475S.
16. Moon, R.C. Pritchard, J.F., Mehta, R.G., Nomides, C.T., Thomas, C.F. and Dinger, N.M. (1989) Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis, 10, 1645-1649.
17. Kelloff, G.J., Crowell, J.A., Boone, C.W. et al. (1994) Clinical development plan: N-(4-hydroxyphenyl)retinamide. J. Cell. Biochem., 20S, 176-196.
18. Moon, R.C., Mehta, R.G. and Detrisac, C.J. (1992) Retinoids as chemopreventive agents for breast cancer. Cancer Detect. Prev., 16, 73-79.
19. Moon, R.C., Thompson, H.J., Becci, P.J. et al. (1979) N-(4-hydroxyphenyl)-retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res., 39, 1339-13146.
20. Formelli, F. and Cleris, L. (1993) Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res., 53, 5374-5376.
21. Veronesi, U., DePalo, G., Costa, A., Formelli, F., Marubini, E. and DelVecchio, M. (1992) Chemoprevention of breast cancer with retinoids. J. Natl Cancer Inst., 12, 93-97.
22. DiVinci, A., Geido, E., Infusini, E. and Giaretti, W. (1994) Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)-retinamide. Int. J. Cancer. 59, 422-426.
23. Mariotti, A., Marcora, E., Bunone, G., Costa, A., Veronesi, U., Pierotti, M.A. and Della Valle, G. (1994) N-(4-Hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. J. Natl Cancer Inst., 86, 1245-1247.
24. Oridate, N., Suzuki, S., Higuchi, M., Mitchell, M.F., Hong, W.K. and Lotan, R. (1997) Involvement of reactive oxygen species in N-(4-hydroxyphenyl)-retinamide-induced apoptosis in cervical carcinoma cells. J. Natl Cancer Inst., 89, 1191-1198.
25. Delia, D., Aiello, A., Lombardi, L. et al. (1993) N-(4-Hydroxyphenyl)-retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res., 53, 6036-6041.
26. Delia, D., Aiello, A., Meroni, L., Nicolini, M., Reed, J.C. and Pierotti, M.A. (1997) Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis, 18, 943-948.
27. Pierce, J.H., Arnstein, P., DiMarco, E., Artrip, J., Kraus, M.H., Lonardo, F., DiFiore, P.P. and Aaronson, S.A. (1991) Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene, 6, 1189-1194.
28. Zhai, Y.F., Beittenmiller, H., Wang, B., Gould, M.N., Oakley, C., Esselman, W.J. and Welsch, C.W. (1993) Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res., 53, 2272-2278.
29. Harris, C.C. (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl Cancer Inst., 88, 1442-1445.
30. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R.D. and Korsmeyer, S.J. (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 334-336.
31. Stampfer, M.R. and Bartley, J.C. (1985) Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. Proc. Natl Acad. Sci. USA, 82, 2394-2398.
32. Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F. and Riccardi, C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Meth., 139, 271-279.
33. Mehta, R.G., Hultin, T.A. and Moon, R.C. (1988) Metabolism of the chemopreventive retinoid N-(4-hydroxyphenyl)retinamide by mammary gland in organ culture. Biochem. J., 256, 579-584.
34. Hultin, T.A., Filla, M.S. and McCormick, D.L. (1990) Distribution and metabolism of the retinoid N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice. Drug Metab. Dispos., 18, 175-179.
35. Telang, N.T. and Sarkar, N.H. (1983) Long-term survival of adult mouse mammary glands in organ culture and their response to a retinoid. Cancer Res., 43, 4891-4900.
36. Bunk, M.J., Telang, N.T., Higgins, P.J., Traganos, F. and Sarkar, N.H. (1985) Effect of N-(4-hydroxyphenyl) retinamide on murine mammary tumor cells in culture. Nutr. Cancer, 7, 105-115.
37. Bunk, M.J., Kinehan, J.J. and Sarkar, N.H. (1985) Biotransformation and protein binding of N-(4-hydroxyphenyl)retinamide in murine mammary epithelial cells. Cancer Lett., 26, 319-326.
38. Dickens, M.S. and Sorof, S. (1980) Retinoid prevents transformation of cultured mammary glands by procarcinogens but not many activated carcinogens. Nature, 285, 581-584.
39. Kao, C.-Y., Oakley, C.S., Welsch, C.W. and Chang, C.-C. (1997) Growth requirements and neoplastic transformation of two types of normal human breast epithelial cells derived from reduction mammoplasty. In vitro Cell Dev. Biol., 33, 282-288.
40. Muller, W.J., Sinn, E., Pattengale, P.K., Wallace, R. and Leader, P. (1988) Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54, 105-115.
41. Bouchard, L., Lamarre, L., Tremblay, P.J. and Jolicocur, P. (1989) Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/ c-neu oncogene. Cell, 57, 931-936.
42. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
43. Winstanley, J., Cooke, T., Murray, G.D. et al. (1991) The long-term prognostic significance of c-erbB-2 in primary breast cancer. Br. J. Cancer, 63, 447-450.
44. Clark, G.M. and McGuire, W.L. (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res., 51, 944-948.
45. Bobrow, L.G., Millis, R.R., Haperfield, L.C. and Gullick, W.J. (1997) c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur. J. Cancer, 33, 1846-1850.
46. Lovekin, C., Ellis, I.O., Locker, A., Robertson, J.F.R., Bell, J., Nicholson, R., Gullick, W.J., Elston, C.W. and Blamey, R.W. (1991) cerbB-2 oncoprotein expression in primary and advanced breast cancer. Br. J. Cancer, 63, 439-443.
47. Gullick, W.J., Love, S.B., Wright, C., Barnes, D.M., Gusterson, B., Harris, A.L. and Altman, D.G. (1991) c-erbB-2 protein overexpression in breast cancer is a risk factor with involved and uninvolved lymph nodes. Br. J. Cancer, 63, 434-438.
48. Igawa, M., Tanabe, T., Chodak, G.W. and Rukstalis, D.B. (1994) N-(4-Hydroxyphenyl)retinamide induces cell cycle specific growth inhibition in PC-3 cells. Prostate, 24, 299-305.
49. Jinno, H., Katdare, M., Osborne, M.P. and Telang, N.T. (1997) Negative growth regulation of oncogene-transformed human mammary epithelial cells by phytochemicals: role of apoptosis. Proc. Am. Assoc. Cancer Res., 38, 208 (abstr. 1400).
50. Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D. and Lippman, M.E. (1990) Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science, 249, 1552-1555.
51. Kazmi, S.M.I., Plante, R.K., Visconti, V. and Lau, C.Y. (1996) Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res., 56, 1056-1062.
52. Fanjul, A.N., Delia, D., Pierotti, M.A., Rideout, D., Qiu, J. and Pfahl, M. (1996) 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J. Biol. Chem., 271, 22441-22446.
53. Dmitrovsky, E. (1997) N-(4-Hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis [Editorial]. J. Natl Cancer Inst., 89, 1179-1181.
54. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H.G., Lin, H.K., Liebermann, D.A., Hoffman, B. and Reed, J.C. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799-1805.
55. Mehta, R.G., Moon, R.C., Hawthorne, M., Formelli, F. and Costa, A. (1991) Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer. 27, 138-141.
56. Mayer, M. and Noble, M. (1994) N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc. Natl Acad. Sci. USA, 91, 7496-7450.
57. Wright, C., Angus, B., Nicholson, S., Sainsbury, J.R.C., Ferndon, J., Cairus, J., Harris, A.L. and Horne, C.H.W. (1992) Expression of c-erbB2 oncoprotein: a prognostic marker in human breast cancer. Cancer Res., 49, 2087-2091.
58. Zeilinger, R., Kury, F., Czerwenka, K. et al. (1989) Her-2/neu amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene, 4, 109-114.
59. Borg, A., Tandon, A.K., Siggurdson, H., Clark, G.M., Ferno, M., Fuqua, S.A.W., Killander, D. and McGuire, W.L. (1990) HER-2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res., 50, 4332-4337.
60. Leitzel, K., Teramoto, Y. and Konrad, K. (1995) Elevated c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol., 13, 1129-1135.
61. Yamaguchi, H., O'Neill, A. and Gelman, R. (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/neu protein. J. Clin. Oncol., 15, 2518-2525.
62. Kelloff, G.J., Fay, J.R., Steele, V.E., Lubet, R.A., Boone, C.W., Crowell, J.A. and Sigman, C.C. (1996) Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epid. Biomarkers Prev., 5, 657-666.
63. Riese, D.J. and Stern, D.F. (1998) Specificity within the EGF family/ErbB receptor family signalling network. Bioassays, 20, 41-48.
64. Zhang, L., Lan, Y.K., Xi, L., Hong, R.L., Kim, D.S.H.L., Chen, C.F., Hortobagyi, G.N., Chang, C.J. and Hung, M.C. (1998) Tyrosine kinase inhibitors, emodin and its derivatives repress HER-2/neu induced cellular transformation and metastasis-associated properties Oncogene, 16, 2855-2863.